Indapta Therapeutics

Vision

Indapta Therapeutics is harnessing the power of naturally occurring NK cells to fight hematologic and solid cancers.

Approach

Indapta Therapeutics is developing a proprietary allogeneic cell therapy designed to substantially improve the cytotoxicity of antibody therapy in multiple cancers. The company has developed allogeneic FcεRIγ-deficient natural killer cells, known as G-NK cells, which have increased potency relative to conventional NK cells. Indapta’s G-NK cells are isolated from healthy donors and do not require genetic engineering, so they can serve as an off-the-shelf treatment that can overcome the cost and inconsistency of autologous T-cell therapies.

Indapta Therapeutics is addressing

• Leap 04 / Prevent and cure cancer